Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has announced its participation in the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jane Chao, Ph.D., CEO and Co-founder, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST.
The presentation will be accessible through a live and archived webcast in the Investor Relations section of Ceribell's website. The company focuses on revolutionizing the diagnosis and management of serious neurological conditions through innovative medical technology solutions.
Details
News Market Reaction – CBLL
The recorded move for CBLL in the trading session of this news was +0.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Standard Time.
Event: 43rd Annual J.P. Morgan Healthcare Conference
Date: Monday, January 13, 2025
Time: 7:30 a.m. PST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About Ceribell, Inc.
Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.